Secukinumab (AIN457) for the treatment of psoriasis

References

• Gudjonsson JE, Elder JT. Psoriasis: epidemiology. ClinDermatol 2007;25(6):535-46
   Web of Science ®Google Scholar
• Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361(5):496-509
   PubMed Web of Science ®Google Scholar
• Boehncke W-H, Schön MP. Psoriasis. Lancet 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978;157(4):238-44
   PubMedGoogle Scholar
• Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. committee for medicinal products for human use (CHMP). Available from: www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500003329 [Last accessed 28 August 2015]
   Google Scholar
• Nast A, Jacobs A, Rosumeck S, Werner RN. Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: A systematic review and meta-analysis. J Invest Dermatol 2015; Epub ahead of print
   PubMedGoogle Scholar
• Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J EurAcadDermatolVenereol 2009;23(Suppl 2):1-70
   Google Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am AcadDermatol 2011;65(1):137-74
   PubMed Web of Science ®Google Scholar
• Giannetti A. Commentary on the European S3-guidelines on the systemic treatment of psoriasis. J EurAcadDermatolVenereol 2010;24(3):368; author reply 368–9
   Web of Science ®Google Scholar
• Schmitt J, Rosumeck S, Thomaschewski G, et al. Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2014;170(2):274-303
   PubMed Web of Science ®Google Scholar
• Puig L, López A, Vilarrasa E, García I. Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points. J Eur Acad Dermatol Venereol 2014;28(12):1633-53
   PubMed Web of Science ®Google Scholar
• Nast A, Sporbeck B, Rosumeck S, et al. Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action. J Invest Dermatol 2013;133(8):1963-70
   PubMed Web of Science ®Google Scholar
• Warren RB, Smith CH, Yiu ZZ, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the british association of dermatologists biologic interventions register (BADBIR). J Invest Dermatol 2015
   Google Scholar
• Chen Y, Qian T, Zhang D, et al. Clinical efficacy and safety of anti-IL-17 agents for the treatment of patients with psoriasis. Immunotherapy 2015;1-15
   Google Scholar
• Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366(13):1190-9
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015;386(9993):541-51
   PubMed Web of Science ®Google Scholar
• Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012;366(13):1181-9
   PubMed Web of Science ®Google Scholar
• Gooderham M, Posso-De Los Rios CJ, Rubio-Gomez GA, Papp K. Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review. Skin Therapy Lett 2015;20(1):1-5
   Google Scholar
• Papp K, Menter A, Strober B, et al. Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2015;72(3):436-9.e1
   PubMed Web of Science ®Google Scholar
• Kopp T, Riedl E, Bangert C, et al. Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature 2015;521(7551):222-6
   PubMed Web of Science ®Google Scholar
• Papp K, Thaçi D, Reich K, et al. Tildrakizumab (MK-3222), an Anti- IL-23p19 Monoclonal Antibody, Improves Psoriasis in a Phase 2b Randomized Placebo- Controlled Trial. Br J Dermatol 2015; Epub ahead of print
   Google Scholar
• Sofen H, Smith S, Matheson RT, et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy ClinImmunol 2014;133(4):1032-40
   PubMed Web of Science ®Google Scholar
• Gordon KB, Duffin KC, Bissonnette R, et al. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. N Engl J Med 2015;373(2):136-44
   PubMed Web of Science ®Google Scholar
• Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am AcadDermatol 2015;73(1):37-49
   PubMed Web of Science ®Google Scholar
• Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 2012;167(3):668-77
   PubMed Web of Science ®Google Scholar
• Bachelez H, van de Kerkhof PCM, Strohal R, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet 2015;386(9993):552-61
   PubMed Web of Science ®Google Scholar
• Papp KA, Menter MA, Abe M, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two, randomised, placebo-controlled, Phase 3 trials. Br J Dermatol 2015; Epub ahead of print
   Google Scholar
• Cosentyx summary of product characteristics. Available from: http://ec.europa.eu/health/documents/community-register/2015/20150115130444/anx_130444_en.pdf [Last accessed 24 July 2015]
   Google Scholar
• Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. SciTransl Med 2010;2(52):52ra72
   Google Scholar
• Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2013;168(2):412-21
   PubMed Web of Science ®Google Scholar
• Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 2013;168(2):402-11
   PubMed Web of Science ®Google Scholar
• Sigurgeirsson B, Kircik L, Nemoto O, et al. Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and/or feet: subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study. J EurAcadDermatolVenereol 2014;28(8):1127-9
   Web of Science ®Google Scholar
• Paul C, Reich K, Gottlieb AB, et al. Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial. J EurAcadDermatolVenereol 2014;28(12):1670-5
   Web of Science ®Google Scholar
• Efficacy and safety of subcutaneous secukinumab for moderate to severe chronic plaque-type psoriasis for up to 1 year (ERASURE). Available from: https://clinicaltrials.gov/ct2/show/NCT01365455
   Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med 2014;371(4):326-38
   PubMed Web of Science ®Google Scholar
• Ohtsuki M, Morita A, Abe M, et al. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study. J Dermatol 2014;41(12):1039-46
   PubMed Web of Science ®Google Scholar
• Safety and efficacy of secukinumab compared to etanercept in subjects with moderate to severe, chronic plaque-type psoriasis (FIXTURE). Available from: https://clinicaltrials.gov/ct2/show/NCT01358578
   Google Scholar
• First study of secukinumab in pre-filled syringes in subjects with chronic plaque-type psoriasis: response at 12 weeks (FEATURE). Available from: https://clinicaltrials.gov/ct2/show/NCT01555125
   Google Scholar
• Blauvelt A, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol 2015;172(2):484-93
   PubMed Web of Science ®Google Scholar
• Judging the efficacy of secukinumab in patients with psoriasis using autoinjector: a clinical trial evaluating treatment results (JUNCTURE). Available from: https://clinicaltrials.gov/ct2/show/NCT01636687
   Google Scholar
• Paul C, Lacour J-P, Tedremets L, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol 2014;29(6):1082-90
   PubMed Web of Science ®Google Scholar
• Efficacy and safety of subcutaneous secukinumab (AIN457) for moderate to severe chronic plaque-type psoriasis assessing different doses and dose regimens (SCULPTURE). Available from: https://clinicaltrials.gov/ct2/show/NCT01406938
   Google Scholar
• Mrowietz U, Leonardi CL, Girolomoni G, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE). J Am AcadDermatol 2015;73(1):27-36.e1
   PubMed Web of Science ®Google Scholar
• Efficacy and safety of intravenous and subcutaneous secukinumab in moderate to severe chronic plaque-type psoriasis (STATURE). Available from: https://clinicaltrials.gov/ct2/show/NCT01412944
   Google Scholar
• Thaçi D, Humeniuk J, Frambach Y, et al. Secukinumab in psoriasis: Randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). Br J Dermatol 2015; Epub ahead of print
   Google Scholar
• Efficacy of secukinumab compared to ustekinumab in patients with plaque-type psoriasis. Available from: https://clinicaltrials.gov/ct2/show/NCT02074982
   Google Scholar
• Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am AcadDermatol 2015;73(3):400-9
   PubMed Web of Science ®Google Scholar
• Plaque psoriasis eficacy and safety with secukinumab (OPTIMISE). ClinicalTrials.gov. Availablefrom https://clinicaltrials.gov/ct2/show/NCT02409667?term=secukinumab+optimise&rank=1 [Last accessed 24 July 2015]
   Google Scholar
• Griffiths C, Reich K, Leonardi CL, et al. Secukinumab demonstrates an acceptable safety profile in moderate to severe plaque psoriasis : Pooled analysis of 10 phase 2/3 studies. P051, 4th World Psoriasis and Psoriatic Arthritis Conference; 8 – 11 July 2015; Stockholm, Sweden
   Google Scholar
• Puel A, Cypowyj S, Bustamante J, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011;332(6025):65-8
   PubMed Web of Science ®Google Scholar
• McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 2014;73(2):349-56
   PubMed Web of Science ®Google Scholar
• Duarte JH. Therapy: Secukinumab improves symptoms of psoriatic arthritis. Nat Rev Rheumatol 2015;11(9):503
   Google Scholar
• Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012;61(12):1693-700
   PubMed Web of Science ®Google Scholar
• Dige A, Støy S, Rasmussen TK, et al. Increased levels of circulating Th17 cells in quiescent versus active Crohn’s disease. J Crohns Colitis 2013;7(3):248-55
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sendid B, Jouault T, Poulain D. Secukinumab failure in Crohn’s disease: the yeast connection? Gut 2013;62(5):800-1
   PubMed Web of Science ®Google Scholar
• Van den Berg WB, McInnes IB. Th17 cells and IL-17 a–focus on immunopathogenesis and immunotherapeutics. Semin Arthritis Rheum 2013;43(2):158-70
   PubMed Web of Science ®Google Scholar
• Teng MW, Bowman EP, McElwee JJ, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies forimmune-mediated inflammatory diseases. Nat Med 2015;21(7):719-29
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Matheson RT, et al. Evidence that aneutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition inpsoriasis. Exp Dermatol 2015;24(7):529-35
   PubMed Web of Science ®Google Scholar
• Johnston A, Guzman AM, Swindell WR, et al. Early tissue responses in psoriasis to the antitumour necrosis factor-α biologicetanercept suggest reduced interleukin-17 receptor expression and signalling. Br J Dermatol 2014;171(1):97-107
   Google Scholar
• Xiong HZ, Gu JY, He ZG, et al. Efficacy and safetyof secukinumab in the treatment of moderate to severe plaque psoriasis: ameta-analysis of randomized controlled trials. Int J ClinExp Med 2015;8(3):3156-72
   Google Scholar
• McInnes IB, Mease PJ, Kirkham B, et al. FUTURE 2 Study Group. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; Epub ahead of print
   Web of Science ®Google Scholar
• Blauvelt A, Lebwohl MG, Bissonnette R. IL-23/IL-17A Dysfunction PhenotypesInform Possible Clinical Effects from Anti-IL-17A Therapies. J Invest Dermatol 2015;135(8):1946-53
   PubMed Web of Science ®Google Scholar